Home » Drug Information » New Medical Therapies™
July 10, 2006
Acologix reported positive results of a phase II trial of AC-100, their novel synthetic peptide to promote dentin formation, at the Annual Meeting of the International Association for Dental Research (IADR) in Brisbane, Australia. Results from the study indicated that the drug was efficacious in stimulating the formation of new dentin when applied to tooth defects at 2 months. The greatest increase in dentin thickness was observed in the deepest cavities (remaining dentin thickness <0.5 mm). No serious adverse events were reported. This randomized, double-blind, placebo-controlled study enrolled 35 patients scheduled for third-molar (wisdom tooth) extraction, who each received 200 ug AC-100 on one tooth and placebo on another applied on days 0, 2 and 4 through dentin tubules.